Lophius Biosciences, a Regensburg, Germany-based biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases, has closed a €1.6m second round of financing.
The round was led by new investor S-Refit, with strong participation from returning backers High-Tech Gruenderfonds and Bayernkapital.
Lophius Biosciences, a spin-off of the Universitätsklinik Regensburg, focuses on the development and marketing of innovative T-cell based test systems for the diagnosis and potential therapy guidance in the fields of transplantation and infectious as well as autoimmune diseases.
The new funds will be used to boost the development of the company with a strong focus on commercialization of existing diagnostic products and the generation of new tests based on its proprietary technology platforms.
In conjunction with the funding, Dr. Michael Lutz has been appointed as Lophius´ new CEO. He replaces the existing managing directors PD Dr. Deml and Marc Akteries, who will remain within the company in leading positions.
Dr. Michael Lutz supports Lophius since September 2009 as coach and advisor.
Before, he was Global General Manager of Cogenics and CEO of Epidauros.